Dyadic International Inc. DYAI
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Dyadic International Inc. (DYAI) is a healthcare company listed in the US with a market value of about $13M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$7M, a net margin of -226.9%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 14% a year, a 5-year average ROIC of -175%.
About Dyadic International
Dyadic International is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $758420 in 2017 to $3M in 2025, growth of about 19.2% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 15% over three years (dilution for shareholders). It spends 70% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $758420 |
| Net income | -$7M | -$7M | -$6M | -$7M | -$10M | -$13M | -$9M | -$8M | -$6M | -$2M |
| Free cash flow | -$7M | -$6M | — | — | — | — | — | — | — | — |
| EPS (diluted) | $-0.20 | $-0.23 | $-0.20 | $-0.24 | $-0.34 | $-0.47 | $-0.34 | $-0.31 | $-0.21 | $-0.07 |
| Net margin | -226.9% | -238.3% | -166.2% | -234.4% | -332.2% | -543.7% | -582.1% | -494.2% | -439.4% | -281.6% |
| ROIC | — | -448.5% | -182.2% | -108.1% | -72.4% | -63.3% | -27.8% | -20.4% | -14.1% | -11.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $4.50, 1276% above the current price; targets range from $2.00 to $7.00; the consensus rating is “Strong buy”; expected EPS is $-0.19 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Dyadic International pay a dividend?
Not currently.
Is Dyadic International a good stock to buy?
We do not give buy or sell advice. Dyadic International scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.